1. Volume 28, Issue 6, Pages 324-329 (December 2012)
Current strategies of anticoagulation therapy for patients with non-valvular atrial fibrillation 
Masahiro Yasaka 
Journal of Arrhythmia 
Volume 28, Issue 6, Pages (December 2012)
DOI: /j.joa
Copyright © 2012 Japanese Heart Rhythm Society Terms and Conditions

2. Fig. 1
Rate of stroke and systemic embolism expressed per subject years in patients treated with a new anticoagulant (dabigatran (2), rivaroxaban, (3) or apixaban (4); gray bars) and in patients treated with warfarin (black bars) as determined in each study. Drug dosage and method of analysis (intention-to-treat or on treatment) are indicated on the x-axis.
Journal of Arrhythmia  , DOI: ( /j.joa )
Copyright © 2012 Japanese Heart Rhythm Society Terms and Conditions

3. Fig. 2
Rate of intracranial bleeding expressed per subject–years in patients treated with a new anticoagulant (dabigatran (2), rivaroxaban, (3) or apixaban (4); gray bars) and in patients treated with warfarin (black bars) as determined in each study. Drug dosage and method of analysis (intention-to-treat or on treatment) are indicated on the x-axis.
Journal of Arrhythmia  , DOI: ( /j.joa )
Copyright © 2012 Japanese Heart Rhythm Society Terms and Conditions

4. Fig. 3
A schematic representation obtained from the Japanese Circulation Society illustrating anticoagulation use in patients non-valvular arterial fibrillation, taken from (5).
Journal of Arrhythmia  , DOI: ( /j.joa )
Copyright © 2012 Japanese Heart Rhythm Society Terms and Conditions

5. Fig. 4
A schematic representation showing the strategy of anticoagulant use according to CHADS2 and CHA2DS2-VASc scores.
Journal of Arrhythmia  , DOI: ( /j.joa )
Copyright © 2012 Japanese Heart Rhythm Society Terms and Conditions

6. Fig. 5
A schematic representation of the coagulation cascade. TF, tissue factor.
Journal of Arrhythmia  , DOI: ( /j.joa )
Copyright © 2012 Japanese Heart Rhythm Society Terms and Conditions

7. Fig. 6
A schematic representation of the intensity of coagulation with continuous (a) and intermittent anticoagulation (b). Broken arrows indicate inhibition of thrombin activity at the trough phase by physiological coagulation inhibitors.
Journal of Arrhythmia  , DOI: ( /j.joa )
Copyright © 2012 Japanese Heart Rhythm Society Terms and Conditions

8. Fig. 7
A schematic representation showing the molecular markers in the coagulation cascade. The broken arrows indicate inhibition.
Journal of Arrhythmia  , DOI: ( /j.joa )
Copyright © 2012 Japanese Heart Rhythm Society Terms and Conditions